Adrenaline is the first-line treatment for anaphylaxis and, therefore, listed as an essential medication for the treatment of anaphylaxis by the World Health Organization (WHO). However, the availability of auto-injector (AAI) forms for use in the first-aid treatment is limited to only 32% of all 195-world countries, mostly highincome countries. The key issues leading to the lack of availability of AAIs include cost but also national regulations, lack of regional evidence about the value of epinephrine and the limited accurate data about the epidemiology of anaphylaxis.
available through official distribution networks, they are available through distribution by special license arrangements, through distribution on a "namedpatient" basis, or through the so-called "suitcase trade". This latter, unofficial, source is unreliable because of the possibility of interruptions in the supply, and shipping and storing AAIs under conditions outside the recommended temperature range, leading to increased possibility of degradation of the adrenaline (epinephrine) content. Although not ideal, in specific situations, where AAIs are not available through official distribution networks, some patients and families can afford to order them online from an international pharmacy or travel to another country to purchase them [8] [9] [10] . Lack of availability of this first-aid medication for immediate injection in an anaphylactic reaction increases the risk of progression to a severe episode and death.
ACTION PLAN TO REACH ADRENALINE AUTO-INJECTORS FOR THE PREVENTION OF

ANAPHYLAXIS WORLDWIDE
According to the WHO constitution, health is defined by state of complete physical, mental and social well-being and not merely the absence of disease or infirmity, and the enjoyable of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, population belief, economic or social condition [11] . With the aim of ensuring good health and care for all, there is a pressing need to step up international and national action on prevention of anaphylaxis and, to understand factors that put subjects at risk of developing anaphylaxis and death secondary to this condition.
A main concern of the allergy community is related to secondary/tertiary preventions focused on accurate diagnosis and management of allergic or hypersensitivity diseases in order to avoid new exacerbations or reactions. In the context of anaphylaxis, since dealing with a multi-system and potentially fatal disorder, all heath care professionals should be prepared to recognize and manage it promptly and properly. Patients, too, should be prepared to recognize and self-treat anaphylaxis promptly. Therefore, AAIs as the first-line treatment should be globally available in both private and public (e.g., school) settings and health networks to be used for any individual who develops anaphylaxis [7] .
Approaches may differ from country to country, depending on the national/ regional policies, regulations and economical status. However, the final purpose of this document is serving as baseline to reach: (I) adequate access to AAI in affordable cost for all patients / societies and (II) disease/patient-specific approaches. For this, we here propose a 5 steps action plan (Table 2) , which should be considered in combination:
(I) To reach accurate anaphylaxis morbidity and mortality statistics (II) To confirm partnership: collaboration with national bodies and stakeholders in order to reach health and/or social security administrations (III) To strengthen awareness (IV) To include AAI into the WHO Model List of Essential Medicine (V) To provide worldwide data regarding the consumption of AAI Countries with different economical conditions have specific priorities and requirements. The proposed action plan should support countries with different needs. For instance, steps I, II and IV would be crucial for middle and low-income countries in which AAI is still missing. On the other hand, steps II and V would allow reach the AAI in affordable prices and cover by the health national securities. Action III is a key step in every country to decrease the number of avoidable deaths. A regular and systematic data collection and dissemination of statistics on diagnoses-based morbidity does not exist at a global level [13] . The reason behind this is that from a methodological and operational point of view, the collection of morbidity statistics is an extremely complex exercise, in particular with regards to comparability of data across countries. Population-based morbidity data mainly uses the ICD as the way of harmonizing data. However, a limited number of ICD-10 codes is able to capture anaphylaxis data. Only two terms in ICD-10 for anaphylaxis are hidden within section T78 of Other and unspecified effects of external causes under the unsatisfactory title Adverse effects, not elsewhere classified. So far these difficulties have hampered attempts to establish a morbidity data collection based on (mainly) administrative data similar to those already existing for causes of death or for health care data based on hospital discharges. Anaphylaxis regional epidemiological data differ considerably according to many variables and it is still unclear whether the increasing incidence published is real or the results reflect different methods used to define and characterize anaphylaxis [14] .
Step I: To reach accurate anaphylaxis morbidity and mortality statistics
Anaphylaxis mortality and morbidity statistics may gain new perspectives with the implementation of the ICD-11 in the forthcoming years. The ICD-11 revision provided the possibility of a better representation of anaphylaxis through the pioneer section "Allergic and hypersensitivity conditions" under the "Disorders of the Immune system" chapter [15, 16] . This achievement was a result of combined international academic and based-evidence trajectory acknowledged by the Joint Allergy Academies, composed by 6 regional international allergy academies (the American Academy of Allergy Asthma and Immunology, the European Academy of Allergy and Clinical Immunology, the World Allergy Organization, the American College of Allergy Asthma and Immunology, the Asia Pacific Association of Allergy, Asthma and Clinical Immunology, and the Latin American Society of Allergy, Asthma and Immunology) and the ICD WHO representatives [12, 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Meanwhile, we have been working to change the WHO mortality coding rules in order to consider anaphylaxis as underlying cause of death in death certificates [30] . The new ICD-11
will not solve all the problems related to population-based mortality and morbidity statistics, such as presence of over or under-diagnosis by coding by persons not experts in this disease (doctors or coders). For this reason, our WHO CC is preparing learning tools to prepare worldwide end-users for the implementation of the ICD-11.
Field-testing and validation procedures have been performed to support the implementation of the ICD-11. The utility of the new "Anaphylaxis" section has been evaluated from the morbidity and mortality perspectives [25] [26] [27] [28] [29] . One of the tasks of our WHO Collaborating Center (WHO CC) is to follow the "Allergic and hypersensitivity conditions" section and promote the required refinements. [14] . Whether this strategy will achieve more financial resources than previous strategies considering anaphylaxis as a disease more frequent than previously though, with a probable increase in its prevalence in the latter decades, mainly due to the increase of atopy and food allergies and therefore with the need for more resources to promote their prevention and treatment is unknown but worth trying, mainly because it is indeed an epidemiological fact that such an approach would eventually prove and the program will be carried on (or disprove and the program will be moved out).
Step II: Confirm partnership: collaboration with national bodies and stakeholders in order to reach health and/or social security administrations
Anaphylaxis epidemiological publications are hampered by the inclusion of all severity degrees of anaphylaxis. Mild reactions in which manifestations are generally limited to one organ or system, such as the skin, usually do not incur any risk of death. The inclusion of these cases in the epidemiological studies provides mistaken perception of high and increasing incidence of severe anaphylaxis. Our focus would be addressing severe reactions in which the risk of mortality is strong and requires additional prevention measures and a coordinated management such as the one provided by the rare disease network in our country. To date, there is no available data regarding severe cases of anaphylaxis in Europe. French data suggests that less than 30,000 people are affected by severe anaphylaxis and, 9.2 per 100,000 personyears based on the University Hospital of Montpellier data [28] . Australian data demonstrated the increasing number of patients at risk of anaphylaxis, from 0.98% in 2009 reaching 1.38% in 2014 in school aged children. In contrast, the number of adrenaline auto-injectors activated (severe cases) per year per 1000 students at risk of anaphylaxis was 6 and 8 in 2010 and 2014 respectively [31] . If taken as isolated data of patients at risk, it can drive readers to think that anaphylaxis is increasing in this country. However, the administration of the treatment as objective data indicates that severe anaphylaxis can be considered as rare disease.
As the only WHO CC for classifications of allergic and hypersensitivity conditions, we intend to establish close collaboration with national bodies in order to implement actions for better patients' care, monitor and prevention, developments in research and launch measures in order to reduce avoidable deaths.
Also, we intend to extend these actions internationally with the support of the WHO-Family of International Classifications, academic and scientific networks, the Joint Allergy Academies, stakeholders and patients' organizations. Our WHO Collaborating
Center will provide the means through which governmental and nongovernmental collaborating parties can combine their strengths to achieve focused objectives, avoiding wasting energy and resources. The position of a WHO CC would allow us a more bilateral dialog with these bodies and faster easier communication with health organizations. Our aim is starting the actions plan applied to anaphylaxis as a model, but we may extend to other allergic and hypersensitivity conditions in the coming period. Human and financial resources will be required and may be achieved through the support from the mentioned bodies involved, robust research projects and structured collaborations. We intend to take all the support to move on the proposed action plan. For that, structured collaborations are under construction.
In the field of anaphylaxis, it is mandatory to sensitize the different levels of the health system in order to trigger more involvement and proactiveness. The first key goal of the work is to ensure the availability of essential medications for patients, therefore the AAI in low and middle-income countries and to promote better management and education in high-income countries.
Step III: To strengthen awareness
The 
Step IV: To include AAI into the World Health Organization Model List of Essential
Medicines
The WHO Model List of Essential Medicine (EML), published by the WHO, contains the medications considered to be most effective and safe to meet most important needs in the health system. The list is frequently used by countries to support the development of their own local lists of essential medicine [6, 32] .
The first list was published in 1977 and included 212 medications. The 20 th edition was published in 2017 and comprises 433 drugs [32] . Although adrenaline (epinephrine) is listed as the treatment of anaphylaxis, the auto-injector form is still missing in the EML. If present in EML, it could be published in national lists of countries in which these drugs are not available. For this reason, the discussions with the WHO EML representatives are ongoing and the proposal will be formally submitted for the forthcoming edition. This move can support argumentations to advocate for the adequate treatment of anaphylaxis worldwide.
Step V: To provide the worldwide data regarding the consumption of AAI Feasibility, effectiveness and affordability of prevention and management strategies are critical to reduce preventable deaths. Knowledge on prescription and consumption of AAI are key data to forecast the auto-injectors market. According to the Global auto-injectors market analysis & forecast, anaphylaxis segment dominated the global auto-injectors market by indication in terms of revenue in 2015 and the trend is projected to sustain throughout the forecast period [33, 34] .
Anaphylaxis segment has been pointed as the most attractive segment in the field with an attractiveness index of 3.55 over the forecast period. Revenue from the anaphylaxis segment is anticipated to register a compound annual growth rate of 15% over 2016-2026, to reach more than US$ 6,000 Mn by 2026 [33] .
Understanding the trends of the market of essential medications, such as the AAI, can support the allergy community to substantiate: (I) accurate data about the burden of global anaphylaxis; (II) national interventions to ensure availability in countries in which these medications are absent; (III) national health policies in order to have them available in both private and public settings; (IV) the dialog with national bodies, regulators and stakeholders to reach medications in affordable price to all or full reimbursement from national security.
Criticism related the availability of AAIs as public health measure can be considered as it only benefits individuals who can also access a correct diagnosis, afford and maintain a safe unexpired supply of the devices. Nevertheless, according to the United States Internal Revenue Service, from the prevention perspective, medications are preventive care when taken by a person who has developed risk factors for a disease that has not yet manifested itself or not yet become clinically apparent, or to prevent the recurrence of a disease from which a person has recovered [35] .
As an example, in 2013, President Obama signed the School Access to Emergency Epinephrine Act into law. This federal legislation provides a financial incentive for states to enact their own laws requiring schools to keep student nonspecific epinephrine auto-injectors in case of an emergency [36] . The key issues leading to the lack of availability of AAIs include cost but also national regulations, lack of regional evidence about the value of epinephrine and the limited accurate data about the epidemiology of anaphylaxis morbidity and mortality data. Over the last several years, an increasing number of clinical databases have been developed to capture reliable anaphylaxis epidemiological data at both national and regional levels [38] [39] [40] [41] [42] [43] [44] [45] . However, a substantial proportion of the current data on the epidemiology of anaphylaxis has come from registries with limited scope and population source. Different methods have been applied in an attempt to reach reliable epidemiological data, but most of the studies have focused on specific triggers or at-risk populations. Lack of harmonized strategies to record anaphylaxis cases hampers collection of comparable epidemiological data. In general, registries are representative sources to reach epidemiological data, and are applied only if the reporting of the conditions is mandatory and the data are validated. For these reasons, regional and international allergy academies support the initiatives to narrow these gaps.
A prioritized research agenda should encapsulate all the previous steps in the frame a global initiative against anaphylaxis. More than calling for the global availability of AAIs for best management of anaphylaxis to prevent undue morbidity and mortality, we here propose an action plan as baseline of a global initiative against anaphylaxis. We strongly believe the combined efforts are a strong public health and societal move, leading to optimal care of allergic patients and best practice of allergology.
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